• Users Online: 123
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others

ORIGINAL ARTICLE

Treatment with Src inhibitor dasatinib results in elevated metastatic potential in the 4T1 murine mammary carcinoma model

Hughes Veronica S, Siemann Dietmar W

Year : 2018| Volume: 1| Issue : 1 | Page no: 30-36

   This article has been cited by
 
1 Carrier-free prodrug nanoparticles based on dasatinib and cisplatin for efficient antitumor in vivo
Lu Yang,Jiaxi Xu,Zheng Xie,Faquan Song,Xin Wang,Rupei Tang
Asian Journal of Pharmaceutical Sciences. 2021;
[Pubmed]  [Google Scholar] [DOI]
2 Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
Seo Yun Moon,Heejin Lee,Seoree Kim,Ji Hyung Hong,Sang Hoon Chun,Hee Yeon Lee,Keunsoo Kang,Ho Shik Kim,Hye Sung Won,Yoon Ho Ko
BMC Cancer. 2021; 21(1)
[Pubmed]  [Google Scholar] [DOI]
3 Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion
Veronica S. Hughes,Dietmar W. Siemann
Oncotarget. 2019; 10(2): 184
[Pubmed]  [Google Scholar] [DOI]
4 Effects of Lidocaine and Src Inhibition on Metastasis in a Murine Model of Breast Cancer Surgery
Thomas P. Wall,Peter D. Crowley,Aislinn Sherwin,Andrew G. Foley,Donal J. Buggy
Cancers. 2019; 11(10): 1414
[Pubmed]  [Google Scholar] [DOI]

 

Read this article